Video-Tumorboard PLUS
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Malignant Melanoma, Telemedicine. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
Primary outcome measures
- Presentation of external patients in the video-tumorboard [Time frame: Day 365]
Secondary outcome measures (5)
- Increase in the proportion of external patients invited to a clinical study [Time frame: Day 365]
- Adherence to tumorboard recommendations for external patients [Time frame: Up to two weeks after inclusion]
- Offer of supportive therapies by the comprehensive cancer center [Time frame: Up to two days after inclusion]
- Duration of the transmission of the tumorboard recommendations [Time frame: Up to two weeks after inclusion]
- "Time to integration" into palliative care [Time frame: Once per patient within two weeks after transmission of the tumorboard recommendation if applicable]
Eligibility criteria
Inclusion criteria
- The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .
Inclusion criteria for patients:
- Minimum age 18 years
- Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:
- Malignant melanoma from stage IIB
- Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.
In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.
Inclusion criteria for external doctors:
- has a medical license
- has dermatological patients who are eligible to be presented in the vTB+
Exclusion criteria
Patients will be excluded from the study if they meet the following criteria:
- Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
- No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 3 centers
- Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn — Bonn
- Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitä — Dresden
- Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster — Münster
Identifiers
NCT: NCT06980740 · BO ff (Multi)-EK-16012025 · 2025-275-b-S